AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03895827 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Passive Referral to Treatment Control
Description: Currently neither first responders or emergency department staff regularly refer people to any kind of substance use after an opioid overdose reversal. In the passive referral condition they will at least get a brochure with information on recently expanded and publicly-funded medication-assisted treatment in their community.
Study NCT06489301 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fractionated Laser Resurfacing
Description: A rejuvenating laser that makes tiny holes in the very superficial part of the skin.
Study NCT05120219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDC tablet
Description: single HR20033 FDC tablet fed, take orally on an empty stomach and then after meals
Study NCT05120219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDC tablet
Description: single HR20033 FDC tablet fasted, take orally after meals and then on an empty stomach
Study NCT05120219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDC tablet
Description: single and multiple doses of HR20033 FDC tablet
Study NCT05397379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC96719
Description: Oral tablets
Study NCT05397379 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Comparator
Study NCT06251700 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ENDO-AID CADe
Description: ENDO-AID CADe will be used during the withdrawal process of the colonscopy
Study NCT06442267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin Injectable Solution
Description: Subcutaneous Enoxaparin will be dosed at 0.5 mg/kg twice daily
Study NCT06442267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Argatroban, 1 Mg/mL Intravenous Solution
Description: Intravenous Argatroban will be administered as a continuous infusion of 0.1-1 µg/kg/min with a target modified thrombin time measured using Hemoclot of 0,40 - 0,60 µg/mL.
Study NCT06442267 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Unfractionated heparin
Description: Unfractionated heparin will be administered as a continuous infusion of 7.5-20 units/kg/h with a target Anti FXa calibrated for UFH of 0.3-0.5 u/mL.
Study NCT05580913 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: 12 weeks of resistance-training performed two times per week
Study NCT05580913 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Resistance training
Description: 12 weeks of resistance-training performed two times per week
Study NCT05669092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: 3mg/Kg iv d1q2w
Study NCT05669092 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CRT
Description: IMRT 50Gy/25fx 625mg/m2 bid d1-5 qw Irinotecan:1、Full wild (GG+6/6): 80mg/m2/week for 5 times 2、Single site mutation (GG+6/7 or GA+6/6): 65mg/m2/week for 5 times 3、Double locus mutation (GG+7/7 or AA+6/6 or GA+6/7): 50mg/m2/week for the 1st, 2nd, 4th and 5th week for 4 times
Study NCT05669092 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SCRT
Description: 25Gy/5fx
Study NCT05669092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XELIRI
Description: Capecitabine: 1000mg/m2 bid d1-14 Irinotecan: 200mg/m2 ivgtt d1 q3w
Study NCT05669092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFRINOX
Description: Irinotecan: 150mg/m2 ivgtt d1 (double locus mutation downregulated to 120mg/m2) Oxaliplatin: 85mg/m2 ivgtt d1 5-FU: 2400mg/m2 ivgtt 46h q2w
Study NCT06271551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal estrogen
Description: Participants (n=155) receiving transdermal estradiol for 12 months.
Study NCT06271551 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Androgen deprivation therapy
Description: Participants (n=155) receiving solely androgen deprivation therapy for 12 months.
Study NCT06271551 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Resistance training
Description: Participants (n=30 in each arm) performing supervised resistance training for six months.
Study NCT06271551 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: Participants (n=30 in each arm) performing supervised resistance training for six months.
Study NCT05779566 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: bone densitometry
Description: bone densitometry every 6 month
Study NCT05114356 — intervention group
Intervention type: DEVICE
Intervention: TIDAL Cervical Interbody Fusion implant
Description: Cervical interbody fusion device
Study NCT05728112 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydrogen Inhalation
Description: The manufacturer will install a hydrogen inhalation machine (hydrogen inhalation or air inhalation) at the subject's home and explain the relevant operation methods. The research executor will pay attention to the LINE group on the first day of installation, and obtain the pre-test basic value data through the google form After (baseline data), continuous hydrogen inhalation was performed daily, and four post-test evaluations were performed before the inhalation and on the 1st, 3rd, 7th, and 14th days after the inhalation was started.
Study NCT05728112 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Ordinary Air Inhalation
Description: The control group was inhaled with the same machine as the experimental group, but the gas was only ordinary air, which was used as a placebo control.
Study NCT05349448 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hylase plus Triamcinolone plus sterile isotonic saline
Description: transforaminal fluroscopic epidural injection
Study NCT05349448 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hylase plus Dexmedetomidine plus Triamcinolone
Description: transforaminal fluroscopic epidural injection
Study NCT05035069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofol
Description: Ciprofol infusion, starting with 0.8 \~ 1mg/kg/h until BIS value below 60 (including 60), and then 0.2 \~ 0.6mg/kg/h until the end of the operation, ciprofol infusion was adjusted to keep the BIS value between 40-60.
Study NCT05035069 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol infusion, starting with 4 \~ 5mg/kg/h until BIS value below 60 (including 60), and then 1 \~ 3mg/kg/h until the end of the operation, propofol infusion was adjusted to keep the BIS value between 40-60.
Study NCT03292822 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Licochalcone A
Description: Licochalcone A is a chalconoid, a type of natural phenols. It can be isolated from root of Glycyrrhiza glabra (liquorice) or Glycyrrhiza inflata. It shows antimalarial, anticancer, antibacterial and antiviral (specifically against influenza neuraminidase) properties in vitro.
Study NCT03292822 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: chemotherapeutic drug
Study NCT05941039 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vestibular training using VR followed by Control
Description: A cross-over design will be used with group one receiving the training intervention for 6 days, a 4-day washout period, and a 6-day no-training period.
Study NCT05941039 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control followed by Vestibular training using VR
Description: Group two will follow the reverse sequence.
Study NCT06422988 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Probiotics
Description: Any exposure to probiotics in first 14 days of life
Study NCT04746937 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitazoxanide
Description: nitazoxanide adjuvant to standard therapy
Study NCT04746937 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Norfloxacin
Description: Standard therapy
Study NCT04746937 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norfloxacin
Description: Standard therapy
Study NCT05259449 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional education program
Description: The education intervention will consist of individual nutritional counselling. The nutritional education program will be conducted every 2 weeks for 12 consecutive weeks, with 20-min counselling sessions by an experienced nutritionist. Participants will be provided with an introduction (in an easy-to-understand manner) regarding the association between T2DM, gut microbiome and dietary habits. Firstly, the diet of the patient should be analysed, to determine which aspects can be improved, such as, total calories intake, amount and types of carbohydrates (highlighting the relevance of fibre), etc. Moreover, some suggestions about the combination of foods and culinary technical in order to manage the glycaemic index of foods will be provided. Finally, those pattern of the Mediterranean diet and some qualitative aspects and aids (as the size of the plat or avoid having the food platter on the table) will be taught the patients.
Study NCT05259449 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional education program
Description: The education intervention will consist of individual nutritional counselling. The nutritional education program will be conducted every 2 weeks for 12 consecutive weeks, with 20-min counselling sessions by an experienced nutritionist. Participants will be provided with an introduction (in an easy-to-understand manner) regarding the association between T2DM, gut microbiome and dietary habits. Firstly, the diet of the patient should be analysed, to determine which aspects can be improved, such as, total calories intake, amount and types of carbohydrates (highlighting the relevance of fibre), etc. Moreover, some suggestions about the combination of foods and culinary technical in order to manage the glycaemic index of foods will be provided. Finally, those pattern of the Mediterranean diet and some qualitative aspects and aids (as the size of the plat or avoid having the food platter on the table) will be taught the patients.
Study NCT05259449 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The High-Intensity Interval Training (HIIT)
Description: 3 sessions per week in a cycle ergometer, with 1-2 days off between sessions, during a total of 12 weeks under the supervision of a personal trainer. HIIT program will consist of 3-5 series of 1 min duration at 90-130% of its maximum power (determined in the first training session), with 90 seconds of rest between sets (estimated total time of the session: 10 minutes). Depending on the number of training session, the load and the series will increase up to 40% more than the maximum load.
Study NCT05259449 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The High-Intensity Interval Training (HIIT)
Description: 3 sessions per week in a cycle ergometer, with 1-2 days off between sessions, during a total of 12 weeks under the supervision of a personal trainer. HIIT program will consist of 3-5 series of 1 min duration at 90-130% of its maximum power (determined in the first training session), with 90 seconds of rest between sets (estimated total time of the session: 10 minutes). Depending on the number of training session, the load and the series will increase up to 40% more than the maximum load.
Study NCT05259449 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The Moderate-Intensity Continuous Training (MICT)
Description: 3 sessions per week in a cycle ergometer, with 1-2 days off between sessions, during a total of 12 weeks under the supervision of a personal trainer. MICT program will consist of sessions of approximately ˜45 min of moderate aerobic exercise (at the intensity at which the maximal fat oxidation was achieved in the laboratory test) in cycle ergometer.
Study NCT05259449 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Moderate-Intensity Continuous Training (MICT)
Description: 3 sessions per week in a cycle ergometer, with 1-2 days off between sessions, during a total of 12 weeks under the supervision of a personal trainer. MICT program will consist of sessions of approximately ˜45 min of moderate aerobic exercise (at the intensity at which the maximal fat oxidation was achieved in the laboratory test) in cycle ergometer.
Study NCT04903431 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Crisis Response Planning for Suicide Risk
Description: Crisis Response Planning is focused on creating personalized set of steps for individuals to follow in case of a crisis and includes individuals' personal warning signs of distress, behavioral coping strategies, reasons for living, social supports to contact, and contact information for professional services, including emergency services. Personalization of the Crisis Response Plan is encouraged, and individuals are instructed to handwrite each step of the Crisis Response Plan on an index card to review.
Study NCT04903431 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Crisis Response Planning for Suicide Risk
Description: Crisis Response Planning is focused on creating personalized set of steps for individuals to follow in case of a crisis and includes individuals' personal warning signs of distress, behavioral coping strategies, reasons for living, social supports to contact, and contact information for professional services, including emergency services. Personalization of the Crisis Response Plan is encouraged, and individuals are instructed to handwrite each step of the Crisis Response Plan on an index card to review.
Study NCT06295172 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lafullen15
Description: Apply a maximum of 1.0 ml for each side of the nasolabial fold using both the test device (Lafullen15) and the control device (Lafullen).
Study NCT05910580 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Screening, Brief Intervention, and Referral to Treatment (SBIRT)
Description: Screening, Brief Intervention, and Referral to Treatment (SBIRT) is an evidence-based approach supported by national healthcare organizations, including the Preventative Services Task Force and the American College of Obstetrics and Gynecologists. Validated tools will efficiently screen an individual's substance use risk. Patients who screen in the risky/harmful range then receive a brief motivational interviewing-based intervention adapted from the evidence-based Brief Negotiated Interview, lasting 5-10 minutes, which provides feedback, helps explore health risks, and motivates change. Individuals who screen in the severe category, indicating a likely AUD/SUD, also receive a brief intervention, aimed at increasing motivation to accept a referral to treatment, and requiring a more intensive approach will also receive a warm-hand off referral to specialty addiction treatment. Procedures for SBIRT delivery will be adapted to the flow of telemedicine visits.
Study NCT06565871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS9531 Injection
Description: Titration administration, SC
Study NCT06565871 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Injection
Description: SC
Study NCT06563661 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The 21-style specific dance exercises
Description: The 21 dance styles (dance in a group), chosen and modified from seven dance styles, including cha-cha, jive, rumba, salsa, waltz, tango, and macarena, were developed by a group of experienced dance and rehabilitation experts and have been previously practised by a group of older adults in our pilot work, demonstrating good feasibility and positive participants' feedback.
Study NCT06563661 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The 21-style specific dance exercises
Description: The 21 dance styles (dance in a group), chosen and modified from seven dance styles, including cha-cha, jive, rumba, salsa, waltz, tango, and macarena, were developed by a group of experienced dance and rehabilitation experts and have been previously practised by a group of older adults in our pilot work, demonstrating good feasibility and positive participants' feedback.
Study NCT05465122 — intervention group
Intervention type: PROCEDURE
Intervention: Carotid Endarterectomy
Description: This is the standard proven therapy for carotid stenosis that involves an arteriotomy followed by removal of plaque and reconstruction of the vessel.
Study NCT05465122 — intervention group
Intervention type: PROCEDURE
Intervention: FDA-approved carotid stents
Description: This is the standard proven therapy for carotid stenosis that involves an arteriotomy followed by removal of plaque and reconstruction of the vessel.
Study NCT05465122 — intervention group
Intervention type: OTHER
Intervention: Intensive Medical Management
Description: INTERVENT risk factor management program to help manage patient's risk factors. The INTERVENT program will provide individualized risk factor counseling sessions (via telephone or internet) at regular interval by healthcare workers who are specially trained to help patients follow the medical management plan.
Study NCT06295172 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lafullen
Description: Apply a maximum of 1.0 ml for each side of the nasolabial fold using both the test device (Lafullen15) and the control device (Lafullen).
Study NCT05077033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: phIL12 GET
Description: intratumoral phIL12 gene electrotransfer
Study NCT05694026 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intense pulsed light
Description: IPL treatment intensity was chosen based on the Fitzpatrick scale as follows: Fitzpatrick scale I, II, III, 10-15 J/cm2 with a 570-nm filter.
Study NCT05694026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diquafosol tetrasodium
Description: 3% Diquafosol tetrasodium eye drops will be used to assess its usefulness in dry eye signs and symptoms
Study NCT05550259 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: protocolized postextubation support
Description: The intervention corresponds to a protocolized use of HFNO or NIV after extubation in accordance with the risk of extubation failure: a) 24H HFNO in patient at low risk of extubation failure b) 48H NIV+/-HFNO in patients at high risk of extubation failure
Study NCT05266807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral capsulized Fecal Microbiota Transplantation
Description: FMT will be administered per os in the form of capsules containing faeces from a healthy donor. Capsules are manufactured at the CHUV pharmacy (University Hospital of Lausanne, Switzerland)
Study NCT05266807 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin or Fidaxomicin
Description: Vancomycin or Fidaxomicin per os as initially prescribed per SoC
Study NCT05266807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin or Fidaxomicin
Description: Vancomycin or Fidaxomicin per os as initially prescribed per SoC
Study NCT06039293 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy and physical activity sessions
Description: The intervention group will receive 10 sessions of cognitive behavioral therapy (CBT) and 6 physical activity sessions over the 12-week period. All Program AACTIVE CBT sessions and exercise sessions will run concurrently and take place virtually using Master of Social Work (MSW) trainees and Movement Science Master of Science students from the University of Michigan.
Study NCT06039293 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Enhanced Usual Care + Diabetes Basics Web Series
Description: Participants will receive the American Diabetes Association Diabetes Basics web series (one video per week for 10 weeks) or Diabetes Basics handouts sent via mail.
Study NCT05375968 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Measurement of Splanchnic venous capacitance(SVC)done at Baseline and after 90 min of 75 g glucose in Healthy Controls POTS patients
Description: While segmental bioimpedance is monitored, continuous positive airway pressure (CPAP) will be applied sequentially at 0, 4, 8, 12, and 16 cm H2O for about 30 seconds each. This positive airway pressure will increase the intrathoracic pressure, which is transmitted to the venous circulation. Pressure (CPAP pressure, X axis) - volume (splanchnic vascular volume measured by segmental impedance and expressed as % change from baseline, Y axis) relationships are then constructed to assess for splanchnic venous capacitance
Study NCT05375968 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Measurement of Splanchnic venous capacitance(SVC)done at Baseline and after 90 min of 75 g glucose in Healthy Controls
Description: While segmental bioimpedance is monitored, continuous positive airway pressure (CPAP) will be applied sequentially at 0, 4, 8, 12, and 16 cm H2O for about 30 seconds each. This positive airway pressure will increase the intrathoracic pressure, which is transmitted to the venous circulation. Pressure (CPAP pressure, X axis) - volume (splanchnic vascular volume measured by segmental impedance and expressed as % change from baseline, Y axis) relationships are then constructed to assess for splanchnic venous capacitance
Study NCT05375968 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Compare change is SVC and SMA flow due to GIP antagonist GIP(3-30)NH2
Description: Participants with POTS will be randomize to either saline versus GIP(3-30)NH2 acute infusion. We will measure changes in their splanchnic venous capacitance and superior mesenteric arterial flow before and after a 75-g oral glucose challenge during supine and 45-degree head-up tilt positions (orthostatic challenge) for up to 3 hr. Notably, we will assess changes in venous capacitance using segmental impedance to measure the effect of graded positive airway pressure (CPAP) on splanchnic blood volume.